Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibuprofen and Naproxen on Sweet Taste and Glucose Detection
NCT06291337Completed
- Sponsor
- Rutgers University
- Start
- Jun 2020
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ibuprofen and naproxen in type 2 diabetes mellitus (T2DM), Alzheimer's disease (AD) and colorectal cancer (CRC), sponsored by Rutgers University. Primary endpoints: Sweet taste intensity ratings at 6 months and Glucose detection thresholds at 6 months. Started Jun 2020; status: completed.
02
Drugs
ibuprofennaproxen
03
Conditions
type 2 diabetes mellitus (T2DM)Alzheimer's disease (AD)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06291337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06291337.